Michael Schlichting

8.4k total citations · 4 hit papers
43 papers, 6.2k citations indexed

About

Michael Schlichting is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Michael Schlichting has authored 43 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 9 papers in Pathology and Forensic Medicine and 9 papers in Cancer Research. Recurrent topics in Michael Schlichting's work include Colorectal Cancer Treatments and Studies (14 papers), Cancer Genomics and Diagnostics (9 papers) and Genetic factors in colorectal cancer (7 papers). Michael Schlichting is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Cancer Genomics and Diagnostics (9 papers) and Genetic factors in colorectal cancer (7 papers). Michael Schlichting collaborates with scholars based in Germany, United States and United Kingdom. Michael Schlichting's co-authors include Eric Van Cutsem, Philippe Rougier, Gunnar Folprecht, Claus-Henning Köhne, Ilhan Celik, Sabine Tejpar, Robert Lim, J. Załuski, Geert D’Haens and Anatoly Makhson and has published in prestigious journals such as New England Journal of Medicine, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Michael Schlichting

41 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine profile →
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

2011 1.4k citations Eric Van Cutsem, Claus-Henning Köhne et al. Journal of Clinical Oncology profile →
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

2017 466 citations Michael Schlichting et al. Journal of Clinical Oncology profile →
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

2012 447 citations Carsten Bokemeyer, Eric Van Cutsem et al. profile →

Peers

Countries citing papers authored by Michael Schlichting

Since Specialization

Citations

This map shows the geographic impact of Michael Schlichting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schlichting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schlichting more than expected).

Fields of papers citing papers by Michael Schlichting

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schlichting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schlichting. The network helps show where Michael Schlichting may publish in the future.

Co-authorship network of co-authors of Michael Schlichting

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Schlichting. A scholar is included among the top collaborators of Michael Schlichting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Schlichting. Michael Schlichting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Engineered vasculature induces functional maturation of pluripotent stem cell-derived islet organoids 2025 ·Developmental Cell ·Yesl Jun, (unknown), (unknown), R. Hugh F. Bender, Weijuan Gong, Vira Kravets, Han Zhu, (unknown), Michael Schlichting, Roberto Gaetani, (unknown), Stephanie J. Hachey, Karen L. Christman, Steven C. George, Christopher C.W. Hughes, Maike Sander	4
2	Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial 2025 ·European Urology Oncology ·Petros Grivas, Jeanny B. Aragon‐Ching, Joaquim Bellmunt, Yohann Loriot, Miguel Á. Climent Durán, Srikala S. Sridhar, Po‐Jung Su, Se Hoon Park, Evgeny Kopyltsov, Yoshiaki Yamamoto, (unknown), (unknown), (unknown), Juliane Manitz, Mairead Kearney, Michael Schlichting, Thomas Powles	0
3	Development of a Conceptual Model of the Patient Experience in Small Cell Lung Cancer: A Qualitative Interview Study 2023 ·Oncology and Therapy ·(unknown), Xinke Zhang, (unknown), (unknown), (unknown), (unknown), Michael Schlichting, Patrick Marquis, Elena Benincasa, (unknown), Vivek Pawar	4
4	Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13 2022 ·Patient ·Cheryl D. Coon, Michael Schlichting, (unknown)	16
5	Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report 2022 ·Value in Health ·Michael Schlichting, Michael Hennig, K. Rüdell, Lori McLeod, Bryan Bennett, James W. Shaw, Lynda Doward, (unknown), Olivier Chassany	8
6	Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework? 2022 ·Value in Health ·(unknown), Nicholas Latimer, Martin Scott, Neil Hawkins, Michael Schlichting, Jixian Wang	2
7	Single-cell chromatin accessibility identifies pancreatic islet cell type– and state-specific regulatory programs of diabetes risk 2021 ·Nature Genetics ·Joshua Chiou, Chun Zeng, Cheng Zhang, Jee Yun Han, Michael Schlichting, Michael Miller, Robert Mendez, Serina Huang, Jinzhao Wang, Yinghui Sui, (unknown), Mei-Lin Okino, Yunjiang Qiu, Ying Sun, Parul Kudtarkar, Rongxin Fang, Sebastian Preißl, Maike Sander, David U. Gorkin, Kyle J. Gaulton	89
8	How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments 2021 ·Value in Health ·Venediktos Kapetanakis, (unknown), Michael Schlichting, K. Jack Ishak, Hemant Phatak, Ting Yu, Murtuza Bharmal	2
9	What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches 2020 ·Applied Health Economics and Health Policy ·Anthony J. Hatswell, Ash Bullement, Michael Schlichting, Murtuza Bharmal	6
10	Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection 2020 ·BMC Medical Research Methodology ·Ash Bullement, (unknown), (unknown), Michael Schlichting, Anthony J. Hatswell, Murtuza Bharmal	13
11	Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay 2020 ·Journal of Thoracic Oncology ·H. Grote, Zheng Feng, Michael Schlichting, Christoph Helwig, Mary Ruisi, Hulin Jin, (unknown), Claudia-Nanette Gann, Zhen Su, Martin Reck, Everett E. Vokes, Keith M. Kerr	25
12	Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma 2019 ·Value in Health ·Murtuza Bharmal, Matthias Hünger, Michael Schlichting	2
13	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma 2019 ·Cancer Immunology Immunotherapy ·Sandra P. D’Angelo, Matthias Hünger, Andrew S. Brohl, Paul Nghiem, Shailender Bhatia, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Michael Schlichting, (unknown), Murtuza Bharmal	17
14	Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies 2019 ·PharmacoEconomics ·Venediktos Kapetanakis, (unknown), Michael Schlichting, K. Jack Ishak, Hemant Phatak, Mairead Kearney, John Stevens, Ágnes Benedict, Murtuza Bharmal	15
15	Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma 2017 ·Health and Quality of Life Outcomes ·Murtuza Bharmal, (unknown), (unknown), Paul Williams, Lisa Mahnke, Alexia Marrel, Michael Schlichting	13
16	Phase 3 Trial of Gemcitabine and Th-302 Compared with Gemcitabine and Placebo in Patients with Pancreatic Adenocarcinoma: the Maestro Trial 2013 ·Annals of Oncology ·Eric Van Cutsem, Robert J. Fram, Michael Schlichting, David P. Ryan	2
17	Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study 2012 ·Journal of Clinical Oncology ·Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, Hans Gelderblom, Jan B. Vermorken, F. Viret, Bengt Glimelius, Elisa Gallerani, Alain Hendlisz, Annemieke Cats, Markus Moehler, Xavier Sagaert, Soetkin Vlassak, Michael Schlichting, Fortunato Ciardiello	94
18	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status breakdown → 2011 ·Journal of Clinical Oncology ·Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P. Nowacki, Stefano Cascinu, I. Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, Ilhan Celik, Philippe Rougier, Fortunato Ciardiello	1441
19	Kras mutations and outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab 2011 ·Annals of Oncology ·Sabine Tejpar, Carsten Bokemeyer, Ilhan Celik, Michael Schlichting, S. Heeger, Eric Van Cutsem	3
20	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer breakdown → 2009 ·New England Journal of Medicine ·Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, (unknown), Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier	2902

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact